Ascendis Pharma A/s Stock News

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective upped by SVB Leerink from $182.00 to $190.00 in a research note released on Monday morning, Analyst Price Targets reports. The brokerage currently has an outperform rating on the biotechnology companys stock. ASND has been the subject of several other research reports. JPMorgan Chase & Co. increased []

–– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial.

58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial.

Wall Street analysts forecast that Ascendis Pharma A/S (NASDAQ:ASND) will post earnings of ($2.78) per share for the current quarter, Zacks reports. Four analysts have provided estimates for Ascendis Pharma A/Ss earnings. The highest EPS estimate is ($1.93) and the lowest is ($3.71). Ascendis Pharma A/S reported earnings of ($3.15) per share during the same []

COPENHAGEN, Denmark, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the Evercore ISI 4th Annual HealthCONx Confe

COPENHAGEN, Denmark, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the Evercore ISI 4th Annual HealthCONx Conference. Company executives will participate in a virtual fireside chat hosted by Evercore ISI.

Related Stocks: ASND , PACB , TVTX , LEGN , KYMR , BLUE , DICE , SRZN , TCRX , TNGX , AMYT , LIFE , APLS , ADCT , PTGX , ASMB , ISEE , SBTX ,

Wall Street brokerages expect Ascendis Pharma A/S (NASDAQ:ASND) to report ($2.78) earnings per share for the current quarter, Zacks reports. Four analysts have issued estimates for Ascendis Pharma A/Ss earnings, with estimates ranging from ($3.71) to ($1.93). Ascendis Pharma A/S reported earnings per share of ($3.15) during the same quarter last year, which would indicate []

Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.

Ascendis Pharma A/S' (ASND) CEO Jan Mikkelsen on Q3 2021 Results - Earnings Call Transcript

COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment fo

– Late-breaking oral presentation will feature a comprehensive review of 58-week results  from the company's Phase 2 PaTH Forward Trial –

COPENHAGEN, Denmark, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new

– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported –

The TransCon platform is designed to optimize the delivery of known drugs to target tissues. The valuation of Ascendis Pharma is largely a reflection of the potential of the platform rather than a sum